dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Azaro Pedrazzoli, Analía Beatriz |
dc.contributor.author | De Vos, Filip |
dc.contributor.author | Sepúlveda, Juan Manuel |
dc.contributor.author | Yung, W. K. Alfred |
dc.contributor.author | Wen, Patrick Y. |
dc.contributor.author | van den Bent, Martin |
dc.date.accessioned | 2021-10-22T11:40:36Z |
dc.date.available | 2021-10-22T11:40:36Z |
dc.date.issued | 2020-01 |
dc.identifier.citation | van den Bent M, Azaro A, De Vos F, Sepulveda J, Yung WKA, Wen PY, et al. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. J Neurooncol. 2020 Jan;146:79–89. |
dc.identifier.issn | 1573-7373 |
dc.identifier.uri | https://hdl.handle.net/11351/6452 |
dc.description | Buparlisib; Capmatinib; Glioblastoma |
dc.description.sponsorship | This study is funded by Novartis Institutes for Biomedical Research (China). A.B. Lassman was supported in part by grants P30CA013696 and UG1CA189960 from the NCI. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Journal of Neuro-Oncology;146 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Glioblastoma multiforme |
dc.subject | Cervell - Càncer - Quimioteràpia |
dc.subject.mesh | Glioblastoma |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Neoplasm Recurrence, Local |
dc.title | A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s11060-019-03337-2 |
dc.subject.decs | glioblastoma |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | recurrencia neoplásica local |
dc.relation.publishversion | https://doi.org/10.1007/s11060-019-03337-2 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [van den Bent M] Erasmus University Medical Center (MC) Cancer Institute, Rotterdam, The Netherlands. [Azaro A] Unitat d’Investigació de Teràpia Molecular, Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [De Vos F] University Medical Center Utrecht, Utrecht, The Netherlands. [Sepulveda J] Hospital Universitario, 12 de Octubre, Madrid, Spain. [Yung WKA] MD Anderson Cancer Center, Houston, TX, USA. [Wen PY] Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA |
dc.identifier.pmid | 31776899 |
dc.identifier.wos | 000500801900001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |